Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 1;2(11):1179-1180.
doi: 10.1001/jamacardio.2017.2922.

Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results

Dae Hyun Kim  1   2 , Hajime Uno  3 , Lee-Jen Wei  4
Affiliations

Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results

Dae Hyun Kim et al. JAMA Cardiol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: D. H. Kim is consultant to Alosa Health, a non-profit educational organization with no relationship to any drug or device manufacturers. H. Uno and L. J. Wei declare no conflicts of interest.

References

    1. Kapadia SR, Leon MB, Makkar RR, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385(9986):2485–2491. - PubMed
    1. Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385(9986):2477–2484. - PubMed
    1. Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13:152. - PMC - PubMed
    1. Uno H, Wittes J, Fu H, et al. Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. Ann Intern Med. 2015;163(2):127–134. - PMC - PubMed
    1. Uno H, Claggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32(22):2380–2385. - PMC - PubMed